Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2017 Oct;49(4):898-905. doi: 10.4143/crt.2016.312. Epub 2017 Jan 18.
We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model.
Patients who underwent curative resection for stage IB lung adenocarcinoma were analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence-free survival and overall survival were compared between these two groups.
A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019).
Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.
我们进行了一项回顾性分析，以确定对于接受完全切除术且根据新开发的复发风险评分模型被定义为高危的病理分期 IB 肺腺癌患者，辅助化疗是否延长总生存期。
对采用新开发的复发风险评分模型分析接受 IB 期肺腺癌根治性切除术的患者，并将其分为低危组和高危组。高危组患者根据是否接受辅助化疗或观察分为两组。比较两组患者的无复发生存率和总生存率。
共纳入 2000 年至 2009 年接受根治性切除术的 328 例患者，其中 110 例（34%）接受辅助化疗，218 例（67%）未接受额外治疗而接受观察。根据我们的风险模型，167 例（51%）为高危，161 例（49%）为低危。低危患者的 5 年无复发生存率和总生存率分别为 84.4%和 91.5%，高危患者分别为 53.9%和 74.7%（p<0.001）。在高危患者中，接受观察的患者 5 年总生存率为 77%，接受辅助化疗的患者为 87%（p=0.019）。
对于接受完全切除术的 IB 期肺腺癌高危患者，辅助化疗可延长总生存期。
